Gilead Sciences (GILD) Files Patent Infringement Suit Against Teva Pharmaceuticals (TEVA)
More News related to GILD
- Gilead Sciences to Present at the NASDAQ OMX 23rd Investor Program
- Gilead Sciences (GILD) and Glaxo (GSK) Agree to Commercialize Viread Hep B Treatment in Five Asian Countries
- Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
- 2010 IR Global Rankings: Invitation for Investors and Analysts Vote for Companies with the Best IR Program and for the Best IR Officer
- Gilead Sciences to Present at the Lazard Capital Markets 6TH Annual Healthcare Conference on Tuesday, November 17
More News related to TEVA
- Cephalon (CEPH) Files Patent Infringement Lawsuit Against Teva (TEVA)
- Unusual 11 Mid-Day Movers 12/01: BIOF, ZN, GSIT, CAGC, RDN Higher; STAA, LTON, ZOOM, OVTI Lower
- Morning Movers 12/01: PEIX, SYMX, GSIT, HDY, GES, BPFH Higher; LTON, OVTI, PLX Lower
- Teva Pharma (TEVA) Submits BLA to U.S. FDA for XM02
- Teva Pharma (TEVA) and Codexis Sign Second Agreement This Year
More News related to Corporate News
- Upside in AMD (AMD) Shares Intensifies, Stock Now Up 8%+ to a New 52-Week High
- Wegener (WGNR) Receives Nasdaq Notice, Going Concern Audit Opinion
- IBM (IBM) and Vanderlande Ind. Sign Four-Year Contract with Amsterdam Airport Schiphol
- General Dynamics (GD) Business Unit Awarded $54M U.S. Marine Corps for 24 Additional COCs
- PG&E (PCG) to Purchase, Operate Major Wind Generating Plant in SoCal
Gilead Sciences, Inc. (Nasdaq: GILD) has filed a lawsuit in U.S. District Court in New York against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA) for infringement of U.S. Patent Numbers 6,642,245 and 6,703,396. Both patents are associated with emtricitabine, a component of Truvada, and are licensed exclusively to Gilead Sciences by Emory University. Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.
The lawsuit is based on an Abbreviated New Drug Application filed by Teva Pharmaceuticals USA, Inc., which seeks approval to manufacture and market a generic version of Truvada before the expiration of both emtricitabine patents.
Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops and commercializes therapeutics in areas of unmet medical need. [SM]
Related Categories
Corporate NewsStocks Mentioned
-0.02
+0.10Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
